Integrating *In-silico* and *In-vitro* Approaches to Screen the Antidiabetic Drug from *Trigonella foenum graecum* Linn.

Twinkle S. Bansode¹,²*, Amit Gupta², Sushama Chaphalkar² and B. K. Salalkar³*

¹Pravara Institute of Medical Sciences (DU), Loni (Bk), Tal. Rahata, Dist. Ahmednagar, (MS), 413736, India.
²Vidya Prathishtan’s School of Biotechnology (VSBT), Baramati, Maharashtra, India.
³Arts, Science and Commerce College, Rahata, Tal-Rahata, Dist. Ahmednagar (MS), 423107, India.

Authors’ contributions

This work was carried out in collaboration between all authors. Authors TSB and BKS designed the study, wrote the protocol and supervised the work. Author TSB carried out all laboratories work and performed the statistical analysis. Authors TSB and BKS managed the analyses of the study. Author TSB wrote the first draft of the manuscript. Authors TSB, AG and SC managed the literature searches and edited the manuscript. All authors read and approved the final manuscript.

ABSTRACT

One of cardiovascular diseases, i.e. Diabetes is reported either through absence of insulin or resistance against insulin. Treatment for diabetic disease related to Type 1 and 2 which includes lots of expenditure every year in the form of capsules or preparing different types of formulation. Recently, more than 400 medicinal plants have been screened to fulfill the requirement of the potent antidiabetic drug. Isolation and purification of effective herbal medicine from these medicinal plants to cure diabetes disease are still challenging. In the present study, our group worked on different enzymes that played a crucial role in the carbohydrate metabolism. For these studies, number of secondary metabolites (19) and enzymes (5) were screened *in silico* for antidiabetic potential. The
result of these studies which showed that alpha amylase formed best interaction with carpaine (an alkaloid) with the lesser binding energy -7.44 kcal/mol as compared with the standard drug Acarbose. Therefore, further *in-vitro* studies were included, the screening of alpha amylase inhibitory activity using different solvent extract. At the concentration of 1 mg/ml FGCE showed highest inhibitory activity i.e. 37.7%. Thin layer chromatography (TLC) was also performed to confirm the number of phytochemicals present in different extract. Overall, these studies claimed that medicinal plant posses a potential antidiabetic activity, but still investigation is required to find out and purify the bioactive compound which can be served as a potent antidiabetic drug.

**Keywords:** Fenugreek; diabetes; molecular docking; TLC; alpha amylase.

**ABBREVIATIONS**

TLC: Thin Layer Chromatography; FGPE: Fenugreek petroleum ether extracts; FGCE: Fenugreek chloroform extracts; FGEE: Fenugreek ethanol extract; FGAE: Fenugreek aqueous extract.

**1. INTRODUCTION**

Bioinformatics, Biochemistry and pharmacology techniques are more common and showed its significant impact on drug designing and also showed its demand for production of drugs against intracellular and extracellular diseases. These drugs should be designed and tested within a short period of time with low risk. Recently, Kirchmair and co-authors mentioned about *in silico* methods for the estimation of chemical interactions with drug metabolizing enzymes including prediction of possible metabolites [1]. In addition, drug basically targets specific molecules that are present in the cellular pathway specific for disease condition or specific against pathogenic microorganism, but remains ineffective to any other important metabolic pathway of the human body [2]. As human being constantly suffers from various life threatening diseases like diabetes, HIV, cancer, etc., it is still challenging to fulfill the demand of an efficient method of drug development to produce an ideal drug [3].

Diabetes mellitus, a chronic metabolic disorder characterized through hyperglycemic condition resulting either through absence of insulin or resistance of available insulin in animal and human model [4]. In diabetes, hyperglycemic condition will appear only when blood glucose level is reported and enhanced in a significant amount and is associated with various abnormalities related to carbohydrate metabolism leading to various cardiovascular and neurological complications. Number of cases related to diabetes enhanced every year and roughly estimated more than 151 million people died per year and suggested that until 2030 the number of people with diabetes is likely to exceed 553 million worldwide. Among diabetes types, Type 2 diabetes is more common and approximately more than 95% people suffering from this disease [5,6]. Type 1 diabetes is caused due to failure of insulin secretion by β-pancreatic cells while Type 2 diabetes occurs due to progressive insulin resistance [7]. As per the literature more than 400 traditional plants have been used for the treatment of diabetes disease [6]. The management of type 2 diabetes could be done by delaying the absorption of glucose through the inhibition of any one of the enzymes that are involved in the carbohydrate metabolism specially the one which hydrolyze or digesting it [8]. It could target inhibition of α-glucosidase, α-amylase [8], β-glucosidase [9], glycogen synthase kinase [10]. Activation of glucokinase is also a targeted therapy for the type 2 diabetes. *In vitro* studies play a crucial role to screen out potent inhibitors of these enzymes from various plants sources [11].

*Trigonella foenum graecum* Linn. or Fenugreek is most popular Indian medicinal plant because of its broad range applications. Fenugreek possesses various pharmacological properties such as, antioxidant activity, chemopreventive activity, anticancer activity, antidiabetic activity, immunomodulatory effect gastroprotective effect etc. [12]. Apart from its medicinal properties fenugreek also used as condiment, incense, as well as used to embalm mummies [13]. Major secondary metabolites present in the fenugreek are alkaloids, flavonoids, Saponins, tannins etc. as mentioned in Table 1 [14,15,16].

In the present study, *in-silico* as well as *in-vitro* attempt is made to understand the possible interaction of the target drugs that would enable to design the potent drug for the treatment of type 2 Diabetes mellitus.
2. MATERIALS AND METHODS

2.1 In-silico Approach (Molecular Docking)

The target proteins Human pancreatic alpha amylase (PDB ID: 1HNY), Human cytosolic beta glucosidase (PDB ID: 2JFE), Human glycogen synthase kinase-3β (PDB ID: 4ACD), Human Glucokinase (PDB ID: 1V4T) Sugar beet alpha-glucosidase (PDB ID: 3W37), were retrieved from protein data bank (PDB) (http://www.rcsb.org/pdb/).

As shown in Table 1, secondary metabolites were identified from fenugreek [13,14]. Various compound structures were retrieved from PubChem database in the SDF format. Ligands were converted to pdbqt file using Open Babel software which is a freeware.

Energy minimization of these ligands and further docking analysis was performed using Autodock module available in PyRx Version 0.8 software (http://pyrx.sourceforge.net/). Total 10 conformers were analyzed for each compound to predict the most favorable interaction and final docking interaction between ligand and protein were analyzed using LigPlot software (https://www.ebi.ac.uk/thornton-srv/software/LIGPLOT/).

2.2 In-vitro Approach

2.2.1 Plant material and extract preparation

Fenugreek seeds were collected from a local market of India and authenticated by the Department of Botany, Padmashri Vikhe Patil College, Pravaranagar (Loni), Tal.Rahata, District Ahmednagar, (MS), India. Seeds were ground into fine powder. The powder was successively extracted by maceration in petroleum ether, chloroform, ethanol and water (increasing order of their polarity) and solvent was evaporated to obtain dry crude extracts. Percent yield of the extract in each solvent was calculated [17,18].

2.2.2 In-vitro Alpha amylase inhibitory activity assay

A total of 250 µl of test samples and standard drug (100-1000 µg/ml) were added to 250 µl of 0.20 mM phosphate buffer (pH 6.9) containing α-amylase (0.5 mg/ml in 0.02 M phosphate buffer, pH-6.9 with 0.006 M Sodium Chloride) solution. The reaction mixture was then pre-incubated at 25°C for 10 min. After incubation, 250 µl of a 1% starch solution (in 0.02 M sodium phosphate buffer, pH 6.9) was added to each tube. The solution was further incubated at 25°C for 10 min. Finally, reaction was terminated with 500 µl of DNSA (3, 5 dinitrosalicylic acid, a chromogen). The test tubes were incubated in a boiling water bath for 5 min and allowed to cool at room temperature. The solution was then diluted with 5 ml distilled water. Absorbance of the reaction mixture was measured at 540 nm. Control shows 100% enzyme activity and prepared using the same procedure replacing the extract with distilled water [19].

The α-amylase inhibitory activity was calculated by using the following formula:

\[
\text{% Inhibition} = \left(\frac{\text{Abs}_{\text{control}} - \text{Abs}_{\text{extracts}}}{\text{Abs}_{\text{control}}}\right) \times 100
\]

IC\textsubscript{50} value was determined graphically.

2.2.3 Chromatographic separation

TLC was performed to confirm the presence of different bioactive compound. Chromatoplates were prepared by mixing silica gel and distilled water in 1:2 ratios and applied on a microscope slide at a uniform thickness of 0.5 mm. After drying, the plates were activated in an oven at 110°C 1 hr. 10 µl of the extract were spotted on a chromatoplate, dried and allowed to develop a chromatogram using an appropriate solvent as shown in Table 3. Developed chromatogram was observed with exposure of the plates to iodine vapor [20,21]. Rf value was calculated using the following formula:

\[
\text{Rf} = \frac{\text{Distance travelled by solute (cm)}}{\text{Distance travelled by solvent (cm)}}
\]

3. RESULTS AND DISCUSSION

3.1 Molecular Docking Analysis

The molecular docking technique is used to estimate the binding affinities and energies of ligand which played a crucial role in the structure based drug design process [22,23]. In our study, total 19 secondary metabolites reported and isolated from fenugreek which was docked with key regulatory enzymes that are important in the diabetes management. The docking result of
Table 1. Binding energies (kcal/mol) obtain during docking analysis of the compounds with their target proteins / enzymes

| Sr. no. | Compounds       | Alpha-amylase | Beta-glucosidase | Glycogen synthase kinase-3β | Glucokinase | Alpha – glucosidase |
|---------|-----------------|---------------|------------------|-----------------------------|-------------|---------------------|
| 1       | Coumarine       | -4.62         | -5.36            | -4.29                       | -4.31       | -4.68               |
| 2       | Diosgenin       | -7.12         | -8.5             | -7.29                       | -6.55       | -6.45               |
| 3       | Galactomannans  | 1.74          | 0.86             | 1.43                        | 0.89        | 1.34                |
| 4       | Gentianin       | -4.54         | -4.51            | -3.79                       | -3.97       | -4.17               |
| 5       | Gitogenin       | -7.08         | -8.32            | -7.67                       | -5.8        | -5.91               |
| 6       | Nicotinic acid  | -2.94         | -3.34            | -4.66                       | -3.92       | -2.84               |
| 7       | Arabinoside isoorientin | -2.25       | -1.23            | -0.79                       | -1.13       | -1.43               |
| 8       | Greacunin       | -1.86         | 0.67             | -0.72                       | 1.78        | -0.29               |
| 9       | Phylic acid     | 4.15          | 5.04             | 0.79                        | 5.2         | 4.66                |
| 10      | Quercetin       | -3.6          | -4.64            | -4.2                        | -3.16       | -3.41               |
| 11      | Sarsapogenin    | -7.06         | -6.93            | -6.58                       | -6.56       | -6.1                |
| 12      | Scopolatin      | -3.79         | -4.93            | -4.87                       | -3.86       | -3.97               |
| 13      | Trigogenin      | -7.28         | -8.34            | -7.83                       | -6.71       | -6.59               |
| 14      | Trigonelline    | -3.95         | -4.01            | -4.41                       | -4.33       | -3.69               |
| 15      | Triterpenoids   | -5.04         | -4.63            | -6.53                       | -4.64       | -5.01               |
| 16      | Vitexins        | -2.38         | -2.35            | -1.99                       | -2.73       | -2.28               |
| 17      | Yamogenin       | -6.86         | -7.27            | -6.97                       | -6.41       | -6.32               |
| 18      | Yuccagenin      | -6.63         | -7.42            | -7.46                       | -6.16       | -6.29               |
| 19      | Carpaione       | -7.44         | -8.17            | -5.97                       | -7.43       | -7.33               |
| 20      | Acarbose        | -0.46         | -2.72            | -2.66                       | -1.87       | -2.05               |

these studies is shown in Table 1. The best docked structure of the ligands was confirmed on the basis of the binding affinity predicted by PyRx, hydrogen bond and hydrophobic interactions [24]. The protein-ligand complex that gives a favorable interaction and was selected for further in-vitro analysis. Lesser binding energy indicates higher binding affinity [25]. Out of 19 secondary metabolites, it is found that carpaine shows favorable interaction with three enzymes, i.e. alpha amylase, glucokinase and alpha glucosidase showing relatively lesser binding energy i.e. -7.44, -7.43 and -7.33 kcal/mol respectively. Best binding poses for alpha amylase, alpha glucosidase and that of glucokinase in complex with carpaine are shown in the Figs. 3A, 3B and 3C respectively. Beta glucosidase-diosgenin complex have a binding energy of -8.5 kcal/mol, while that of glucogen synthase kinase 3β – tigogenin complex have binding energy -7.83 kcal/mol (Table 1). The best binding pose for beta glucosidase with diosgenin is shown in Fig. 1b, while best binding pose for glucogen synthase kinase is shown in Fig. 3D. In comparison with standard drug all ligands show lesser binding energy. Moving towards the hydrogen bonds it is clear from the complex that among the five complexes only two complexes form hydrogen bond with their ligands (Figs. 2 and 1a). Carpenter forms a hydrogen bond with the Gln63 residue of the A chain of the alpha amylase and the bond distance is 3.28Å (Fig. 2A).

Alpha glucosidase does not form any hydrogen bond, but it does interact with carpaine by hydrophobic interaction (Fig. 2B). Similarly Glycogen synthase kinase 3β does not form any hydrogen bond with tigogenin but interact with hydrophobic non-covalent interactions (Fig. 2D). With the Glucokinase carpaine interact by forming hydrogen bond with Asn204 and Asn 231 with bond distance 3.00Å and 2.77Å respectively (Fig. 2C). The hydrogen bond is very much important for the directionality and specificity, which is required for the selective molecular interaction [26]. Trp58, Tr59, Tyr62, Leu162, Thr163, Asp300, His305 are the residue of the A chain of the alpha amylase those interact with carpaine by hydrophobic interactions (Fig. 2A). Hydrophobic interaction of carpaine with glucokinase clears that Asn204, Asp205, Thr206, Gly229, Cys230, Asn231, Glu256, Gln287, Glu290 amino acid residues of glucokinase are involved (Fig. 2C). As both alpha amylase and glucokinase showed best docking interaction the two enzymes were the topic of interest for further in-vitro analysis. In drug designing, alpha amylase inhibition while glucokinase activation is the important aspect.
3.2 In-vitro Alpha Amylase Inhibitory Activity Assay Analysis

Various carbohydrates hydrolyzing enzymes are targeted to decrease the hyperglycemia. These drugs are very much effective in the regulation of glucose metabolism without stimulating or activating the insulin / insulin secretion [27]. Acarbose and Vaglibose are the examples which are considered to be inhibited alpha amylase activity [28]. Alpha amylase inhibitors are a kind of anti-nutrients which suppress hydrolysis of starch [29]. In the present study Acarbose was taken as a control to compare our results. Acarbose showed the highest percent inhibition 65% at the concentration of 1 mg/ml (Table 2), while at the same concentration FGCE showed the highest percent inhibition value at 37.7% (Table 3). The other three plants extract i.e FGPE, FGEE and FGAE showed the percent inhibition of 26.62%, 27.72%, and 19.4% respectively at 1 mg/ml concentration (Table 3). IC<sub>50</sub> of the control Acarbose was 52.21 (µg /ml) while FGCE was 1622 (µg /ml). Our values were well matched with literature [30]. It can be thought that the potent antidiabetic activity shown by the different extract may be due to the presence of various phytochemicals like phenols, flavonoids, saponins, steroids, alkaloids, terpenoids etc. as a bioactive compound [31].

To detect the bioactive compounds present in the fenugreek extracts we proceeded further for the separation of these phytochemicals by TLC method.

Table 2. Alpha amylase inhibition by standard drug Acarbose. Tests were carried out in triplicate manner and values are expressed as the mean ± standard deviation. The IC<sub>50</sub> value is nothing but the concentration of inhibitor which inhibits 50% of its activity under the assayed conditions.

| Standard drug | Concentration (µg / ml) | % Inhibition | IC<sub>50</sub> values (µg / ml) |
|---------------|------------------------|--------------|--------------------------|
| Acarbose      | 100                    | 42.15 ± 0.68 | 52.21                    |
|               | 200                    | 57.88 ± 2.42 |                          |
|               | 400                    | 62.24 ± 0.53 |                          |
|               | 600                    | 63.76 ± 0.96 |                          |
|               | 800                    | 64.66 ± 1.26 |                          |
|               | 1000                   | 65.99 ± 1.76 |                          |

3.3 TLC Fingerprinting

TLC fingerprinting of fenugreek plant extract using different solvent confirmed the presence of diverse phytochemicals while their Rf values reveal us about their polarity, high Rf value indicates the low polarity and vise versa [32,19]. Investigation of phytochemicals that are present in fenugreek, found that petroleum
ether extract contains two compounds, chloroform plant extract contains one compound, ethanol plant extract contains total four compounds while aqueous extract contains one compound (Table 4). These compounds can be considered as bioactive compounds. TLC study at least gives an idea about the possibilities of the compounds those might be present in the different extract and responsible for antidiabetic activity. Petroleum ether generally extracts the alkaloids, terpenoids, coumarins etc. whereas chloroform extracts for terpenoids and flavonoids; ethanol extracts for tannins, polyphenols, polyphenols, polyacetylenes, flavonol, terpenoids and sterols while aqueous extract for anthocyanins, saponins, etc. [33].
Table 3. Alpha amylase inhibition by plant extracts of different solvents. Tests were carried out in triplicate manner and values are expressed as the mean ± standard deviations. The IC_{50} value is nothing but the concentration of inhibitor which inhibits 50% of activity under the assayed conditions.

| Standard drug | Concentration (µg/ml) | % Inhibition       | IC_{50} values (µg/ml) |
|---------------|-----------------------|--------------------|------------------------|
| FGPE          | 100                   | 14.43 ± 1.44       | 1051                   |
|               | 200                   | 16.44 ± 0.13       |                        |
|               | 400                   | 18.76 ± 3.01       |                        |
|               | 600                   | 19.96 ± 3.30       |                        |
|               | 800                   | 22.23 ± 3.27       |                        |
|               | 1000                  | 26.62 ± 2.29       |                        |
| FGCE          | 100                   | 13.50 ± 1.66       | 1622                   |
|               | 200                   | 14.47 ± 0.75       |                        |
|               | 400                   | 16.48 ± 0.18       |                        |
|               | 600                   | 22.01 ± 1.17       |                        |
|               | 800                   | 26.77 ± 1.11       |                        |
|               | 1000                  | 37.72 ± 1.00       |                        |
| FGEE          | 100                   | 14.69 ± 1.78       | 3063                   |
|               | 200                   | 17.58 ± 1.25       |                        |
|               | 400                   | 18.8 ± 0.43        |                        |
|               | 600                   | 19.62 ± 0.27       |                        |
|               | 800                   | 21.36 ± 2.46       |                        |
|               | 1000                  | 27.72 ± 2.35       |                        |
| FGAE          | 100                   | 10.93 ± 1.52       | 4547                   |
|               | 200                   | 12.93 ± 0.75       |                        |
|               | 400                   | 16.79 ± 0.06       |                        |
|               | 600                   | 16.65 ± 0.70       |                        |
|               | 800                   | 17.67 ± 0.31       |                        |
|               | 1000                  | 19.4 ± 2.00        |                        |

Fig. 3. Best binding poses for the enzyme ligand complexes. Cartoon represents the different enzymes while colored dotted surface represents the compounds showing the energetically favorable position that fit into the target protein. A. Carpaine in complex with alpha amylase
B. Carpaine in complex with Alpha glucosidase C. Carpaine in complex with Glucokinase
D. Trigogenine in complex with glycogen synthase kinase 3β.
Table 4. TLC result of different extracts of *Trigonella foenum graecum* Linn visualized by iodine chamber

| Sr no | Extract   | Solvent system used                     | Rf value   |
|-------|-----------|-----------------------------------------|------------|
| 1     | Petroleum ether | Chloroform: Ethyl acetate (3:1) | 0.8, 0.2   |
| 2     | Chloroform       | Chloroform: Ethyl acetate (4:6)      | 0.94       |
| 3     | Ethanol          | Ethyl acetate: Methanol: Water (5:1:1) | 0.97, 0.54, 0.35, 0.10 |
| 4     | Aqueous          | Toluene: Ethyl acetate (4:1)          | 0.25       |

4. CONCLUSION

By analyzing the result we have concluded that secondary metabolites isolated from fenugreek possess and showed potent antidiabetic activity. *In-silico* studies hypothesized that among the four enzymes studied alpha amylase enzyme in complex with the carpine alkaloid would prove the best for further regulation of the antidiabetic activity. *In vitro* assay confirmed that the phytochemicals present in the different fenugreek extract are responsible for antidiabetic activities. These phytochemicals extracted in different plant extracts includes alkaloids, terpenoids, flavonoids, tannins, polyphenols, polyacetylenes, sterols, saponins are responsible for this activity. Further investigation is required to find out and purify the bioactive compound which can be served as a potent antidiabetic drug.

ACKNOWLEDGEMENTS

All authors are highly grateful to Pravara Institute of Medical Sciences (Deemed University) and VSBT Baramati, for providing the support to conduct research work. Reviewers and Editor of this article are also greatly acknowledged for their tremendous effort in reviewing the manuscript.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Kirchmair J, Williamson MJ, Tyzack JD, Tan L, Bond PJ, Bender A, Glen RC. J Chem Inf Model. 2012;52:617.
2. Ramanathan K, Karthick H, Arun N. Structure based drug designing for diabetes mellitus. J Proteomics Bioinform. 2010;3:310-313. DOI: 10.4172/jpb.1000157
3. Mandal S, Moudgil MN, Mandal SK. Rational drug design. European Journal of Pharmacology. 2009;625(1):90-100.
4. Mihailova S, Tsvetkova A, Todorova A. Pharmacological trends in the treatment of diabetes type 2 - New classes of antidiabetic drugs. International Archives of Integrated Medicine. 2015;2(4):223-228.
5. Al-fayyadh MS. Evaluation of some vitamins related with glycemic index in type 2 diabetes patients. Int J Adv Res. 2016;4(5):116-124.
6. Piero NM, Njagi MJ, Kibiti MC, Ngeranwa JNJ, Njagi NM, Njue WM, Gathumbi PK. Herbal management of diabetes mellitus: A rapidly expanding research avenue. Int J Curr Pharm Res. 2012;4(2):1-4.
7. Madeswaran A, Umamaheswari M, Asokkumar K, Sivashanmugam T, Subhadradevim V, Jagannath P. *In silico* docking evaluation of α-amylase inhibitory activity of butein and tricetin. J Comput Method Mol Design. 2014;14:65-72.
8. Hashim A, Khan MS, Khan MS, Baig MH, Ahmad S. Antioxidant and α-amylase inhibitory property of *Phyllanthus virgatus* L.: An *in vitro* and molecular interaction study. Bio Med Research International. 2013;1-12.
9. Parizadeh H, Garampalli RH. Evaluation of some lichen extracts for β-glucosidase inhibitory as a possible source of herbal anti-diabetic drugs. American Journal of Biochemistry. 2016;6(2):46-50.
10. Henriksen EJ, Dokken BB. Role of glycogen synthase kinase-3 in insulin resistance resistance and type 2 diabetes. Current Drug Targets. 2006;7(11):1435-1441.
11. Kumari V, Li C. Comparative docking assessment of glucokinase interactions with its allosteric activators. Curr Chem Genomics. 2008;2:76-89.
12. Toppo FA, Akhand R, Pathak AK. Pharmacological actions and potential uses of *Trigonella foenum-graecum*: A review. Asian Journal of Pharmaceutical and Clinical Research. 2009;2:4.

13. Al-Asadi JN. Therapeutic uses of fenugreek (*Trigonella foenum-graecum* L.). American Journal of Social Issues and Humanities. 2014;21:36.

14. Snehlata HS, Payal DR. Fenugreek (*Trigonella foenum-graecum* L.): An overview. Int J Curr Pharm Rev Res. 2012;2(4):169-187.

15. Mullaiacharam AR, Geetali D, Uma M. Medicinal values of fenugreek—A review. Res. J. Pharm. Biol. Chem. Sci. 2013;4:1304-1313.

16. Nathiya S, Durga M, Devasena T. Therapeutic role of *Trigonella foenum-graecum* (Fenugreek)-A review. Int. J. Pharmaceut. Sci. Rev. Res. 2014;27:74-80.

17. Hossain MA, Al-Hdhrami SS, Welli AM, Al-Riyami Q, Al-Sabahi JN. Isolation, fractionation and identification of chemical constituents from the leaves crude extracts of *Mentha piperita* L grown in Sultanate of Oman. Asian Pacific Journal of Tropical Biomedicine. 2014;4:S368-S372.

18. Arokiyaraj S, Perinbam K, Agastian P, Kumar RM. Phytochemical analysis and antibacterial activity of *Vitex agnus-castus*. International Journal of Green Pharmacy. 2009;2:162-164. Rev Res. 2009;5(2):38-42.

19. Kazeem MI, Raimi OG, Balogun RM, Ogundajo AL. Comparative study on the α-amylase and α-glucosidase inhibitory potential of different extracts of *Blighia sapida* Koenig. American Journal of Research Communication. 2013;1(7):178-192.

20. Jayashree D. Phytochemicals analysis and tlc fingerprinting of methanolic extracts of three medicinal plants. Int Res J Pharm. 2013;4(6):123-6.

21. Sreejamoole KL, Radhakrishnan CK. Preliminary qualitative chemical evaluation of the extracts from mussel *Perna viridis*. Int J Phar Sci Rev Res. 2010;5(2):38-42.

22. Angadi KK, Gundampati RK, Jagannadham MV, Kendru A. Molecular docking studies of guggulsterol from *Nymphea pubescens* with target glucokinase (GK) related to type-II diabetes. Journal of Applied Pharmaceutical Science. 2013;3(2):127-131.

23. Herowati R, Widodo GP. Molecular docking studies of chemical constituents of *Tinospora cordifolia* on glycogen phosphorylase. Procedia Chemistry. 2014;13:63-68.

24. Datar PA, Deokule TA. Design and synthesis of thiazolole derivatives as antidiabetic agents. Medicinal Chemistry. 2014;4(4):390-399.

25. Taktaz F. Docking studies of inhibitory effect of herbal compounds on human pancreatic alpha-amyrase. Journal of Current Research in Science. 2014;2(6):675-679.

26. Hubbard RE, Kamran Haider M. Hydrogen bonds in proteins: Role and strength. In: eLS. John Wiley & Sons Ltd, Chichester; 2010.

Available: http://www.els.net

DOI:10.1002/9780470015902.a0003011.p

27. Kumar BA, Lakshman K, Nandeesh R, Kumar PA, Manoj B, Kumar V, Shekar DS. *In vitro* alpha-amyrase inhibition and *in vivo* antioxidant potential of *Amaranthus spinosus* in alloxan-induced oxidative stress in diabetic rats. Saudi Journal of Biological Sciences. 2011;18(1):1-5.

28. Paul T, Banerjee S. *In-vitro* evaluation of α-amylase inhibitory activity & antioxidant potential of *Pteris vittata* L. with special reference to its hptlc profile. International Journal of Pharma and Bio Sciences. 2013;494-503.

29. Sudha P, Zinjarde SS, Bhargava SY, Kumar AR. Potent α-amylase inhibitory activity of Indian Ayurvedic medicinal plants. BMC Complementary and Alternative Medicine. 2011;11(1):1.

30. Jyothi D, Koland M. Design, development and evaluation of anti-diabetic liquid oral preparation from extract of fenugreek. Int. J. Pharma. Res. Biosci. 2013;2(4):39.

31. Sumathy A. *In-vitro* alpha amyrase inhibitory and anti-oxidant activities of Ethanolic leaf extract of croton bonplandianum. Asian Journal of Pharmaceutical and Clinical Research. 2013;6(4):32-36.

32. Talukdar AD, Choudhury MD, Chakraborthy M, Dutta BK. Phytochemical screening and
TLC profiling of plant extracts of *Cyathea gigantea* (Wall. Ex. Hook.) Haltt. and *Cyathea brunoniana* Wall. ex. Hook (Cl. & Bak.). Assam University Journal of Science and Technology. 2010;5(1):70-74.

33. Tiwari P, Kumar B, Kaur M, Kaur G, Kaur H. Phytochemical screening and extraction: A review. Internationale Pharmaceutica Scientia. 2011;1(1):98-106.

34. Tribolo S, Berrin JG, Kroon PA, Czjzek M, Juge N. The crystal structure of human cytosolic β-glucosidase unravels the substrate aglycone specificity of a family 1 glycoside hydrolase. Journal of Molecular Biology. 2007;370(5):964-975.